Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AgelessHAIR is a prescription-strength topical solution developed by AgelessRx for the treatment of androgenetic alopecia (pattern hair loss). The formulation typically utilizes a synergistic combination of three active pharmaceutical ingredients: minoxidil, finasteride, and tretinoin. Minoxidil acts as a vasodilator and potassium channel opener, which enhances blood flow to the hair follicles and stimulates the transition of follicles from the telogen (resting) phase to the anagen (growth) phase. Finasteride is a 5-alpha reductase inhibitor that reduces the local concentration of dihydrotestosterone (DHT), the primary androgen responsible for follicular miniaturization. Tretinoin, a retinoid, is included to increase the permeability of the scalp, thereby enhancing the absorption and efficacy of minoxidil. By delivering these agents topically, AgelessHAIR aims to provide localized therapeutic effects while potentially reducing the systemic side effects associated with oral administration of hair loss medications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AgelessHAIR.